News
COEP
0.1860
+0.76%
0.0014
COEPTIS THERAPEUTICS HOLDINGS INC: SIGNS BINDING LOI TO ACQUIRE KEY ASSETS FROM A RISK MITIGATION SOFTWARE CO
Reuters · 1d ago
Press Release: Coeptis Therapeutics Unveils New -2-
Dow Jones · 1d ago
Press Release: Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies
Dow Jones · 1d ago
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Weekly Report: what happened at COEP last week (1202-1206)?
Weekly Report · 4d ago
Coeptis Therapeutics to acquire NexGenAI Affiliates Network
TipRanks · 12/03 13:21
Press Release: Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
Dow Jones · 12/03 13:15
Weekly Report: what happened at COEP last week (1125-1129)?
Weekly Report · 12/02 10:03
Weekly Report: what happened at COEP last week (1118-1122)?
Weekly Report · 11/25 09:59
Weekly Report: what happened at COEP last week (1111-1115)?
Weekly Report · 11/18 09:58
Weekly Report: what happened at COEP last week (1104-1108)?
Weekly Report · 11/11 10:03
COEPTIS THERAPEUTICS ANNOUNCES PHASE 1 DATA ON DVX201 FOR COVID-19 TREATMENT HAS BEEN ACCEPTED FOR PUBLICATION IN MOLECULAR THERAPY METHODS AND CLINICAL DEVELOPMENT
Reuters · 11/07 13:07
COEPTIS THERAPEUTICS HOLDINGS: ENTERS $20 MILLION SEPA WITH YORKVILLE - SEC FILING
Reuters · 11/06 22:41
Weekly Report: what happened at COEP last week (1028-1101)?
Weekly Report · 11/04 10:03
Weekly Report: what happened at COEP last week (1021-1025)?
Weekly Report · 10/28 09:59
Coeptis Therapeutics Expands License Agreement With Deverra To Include Pandemic Preparedness, And Emergency Use; Expansion Includes The Use Of Unmodified NK Cells In Treating Viral Infections, Pandemic-Related Illnesses, And Emergency Stockpiling For Future Health Crises
Benzinga · 10/24 12:20
Coeptis Therapeutics expands license agreement with Deverra
TipRanks · 10/24 12:10
COEPTIS THERAPEUTICS EXPANDS LICENSE AGREEMENT WITH DEVERRA TO INCLUDE PANDEMIC PREPAREDNESS, AND EMERGENCY USE
Reuters · 10/24 12:07
Weekly Report: what happened at COEP last week (1014-1018)?
Weekly Report · 10/21 09:58
BUZZ-U.S. STOCKS ON THE MOVE-Johnson & Johnson, Boeing, Wolfspeed
Reuters · 10/15 12:40
More
Webull provides a variety of real-time COEP stock news. You can receive the latest news about Coeptis Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About COEP
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen chimeric antigen receptor (CAR) T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells are genetically engineered to recognize cancer cells to target and destroy them.